Kromek Group PLC Notice of Results (5080V)
December 14 2021 - 2:00AM
UK Regulatory
TIDMKMK
RNS Number : 5080V
Kromek Group PLC
14 December 2021
14 December 2021
Kromek Group plc
("Kromek" or the "Group")
Notice of Results
Kromek (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and
CBRN segments, gives notice that it will be announcing its interim
results for the six months ended 31 October 2021 on 18 January
2022.
Dr Arnab Basu, Chief Executive Officer, and Paul Farquhar, Chief
Financial Officer, will be hosting a presentation to analysts at
9.30am GMT on the day via webcast. To register to participate,
please contact: amysmart@luther.co.uk.
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO +44 (0)1740 626 060
Cenkos Securities plc (Nominated Adviser
and Broker)
Giles Balleny/Camilla Hume (NOMAD)
Julian Morse (Sales) +44 (0)20 7397 8900
Luther Pendragon (Financial PR)
Harry Chathli
Claire Norbury +44 (0)20 7618 9100
About Kromek Group plc
Kromek Group plc is a leading developer of radiation detection
and bio-detection technology solutions for the advanced imaging and
CBRN segments. Headquartered in County Durham, UK, Kromek has
manufacturing operations in the UK and US, delivering on the vision
of enhancing the quality of life through innovative detection
technology solutions.
The advanced imaging segment comprises the medical (including CT
and SPECT), security and industrial markets. Kromek provides its
OEM customers with detector components, based on its core cadmium
zinc telluride (CZT) platform, to enable better detection of
diseases such as cancer and Alzheimer's, contamination in
industrial manufacture and explosives in aviation settings.
In CBRN, the Group provides nuclear radiation detection
solutions to the global homeland defence and security market.
Kromek's compact, handheld, high-performance radiation detectors,
based on advanced scintillation technology, are primarily used to
protect critical infrastructure and urban environments from the
threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN
segment. These consist of fully automated and autonomous systems to
detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange,
under the trading symbol 'KMK'.
Further information is available at www.kromek.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFFEFADEFSELE
(END) Dow Jones Newswires
December 14, 2021 02:00 ET (07:00 GMT)
Kromek (LSE:KMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kromek (LSE:KMK)
Historical Stock Chart
From Jul 2023 to Jul 2024